Hologic Closes $3.8B Deal for Gen-Probe
BEDFORD, Mass. (AP) — Medical device maker Hologic Inc. said Wednesday that it completed its $3.8 billion acquisition of diagnostic test maker Gen-Probe Inc.
Gen-Probe's products include tests for sexually transmitted diseases. Hologic expects the deal to deepen its women's health focus and make it a major provider of STD diagnostics.
Hologic, based in Bedford, Mass., agreed in April to pay $82.75 for each share of Gen-Probe. The San Diego company has about 45.3 million outstanding shares, so the deal is worth about $3.8 billion.
With the closing of the deal, Gen-Probe common stock stopped trading and will no longer be listed on the Nasdaq.